From another recent study, 125 NSCLC patients who received a PD-1/PD-L1 inhibitor were enrolled to investigate whether baseline serum IL-6 levels may predict ICI treatment efficacy. The gene discussed is IL6; the disease is non-small cell lung carcinoma.